Enanta Pharmaceuticals (ENTA) Preferred Dividend Payments (2012 - 2013)
Enanta Pharmaceuticals (ENTA) reported Preferred Dividend Payments of -$11.1 million for Q3 2013, down 204.86% on a YoY basis from $10.6 million in Q3 2012, and down 995.82% quarter-over-quarter from $1.2 million in Q1 2013.
Enanta Pharmaceuticals (ENTA) Preferred Dividend Payments (2012 - 2013) Analysis & Trends
Enanta Pharmaceuticals has reported Preferred Dividend Payments for 2 years, with the latest figure at -$11.1 million in Q3 2013.
- For the quarter ending Q3 2013, Preferred Dividend Payments fell 204.86% year-over-year to -$11.1 million; the trailing twelve-month figure through Sep 2013 stood at -$8.6 million (changed N/A YoY), and the FY2013 full-year result was $2.5 million, down 82.77% from the prior year.
- Preferred Dividend Payments for Q3 2013 stood at -$11.1 million, down from $1.2 million in the prior quarter.
- The five-year high for Preferred Dividend Payments was $10.6 million in Q3 2012, with the low at -$11.1 million in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | -11.14 Mn |
| Mar 31, 2013 | 1.24 Mn |
| Dec 31, 2012 | 1.28 Mn |
| Sep 30, 2012 | 10.63 Mn |
| Jun 30, 2012 | 1.33 Mn |
| Mar 31, 2012 | 1.33 Mn |